ArticlePloS one2018
Influence of the time interval from diagnosis to treatment on survival for early-stage liver cancer.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Bypassing pleural aspiration for early tissue diagnosis in suspected pleural malignancy: Development and external validation of a predictive model using supervised machine learning.Qatar medical journal · 2026Article
- Racial/Ethnic Differences and Effects of Clinical/Socioeconomic Factors on Time from Diagnosis to Treatment in Pancreatic Cancer.Journal of gastrointestinal cancer · 2025Article
- Challenges in Liver Transplantation for Hepatocellular Carcinoma: A Review of Current Controversies.Cancers · 2024Review
- Development of machine learning models for patients in the high intrahepatic cholangiocarcinoma incidence age group.BMC geriatrics · 2024Article
- Machine learning-based radiomic analysis and growth visualization for ablation site recurrence diagnosis in follow-up CT.Abdominal radiology (New York) · 2024Article
- The impact of waiting time and delayed treatment on the outcomes of patients with hepatocellular carcinoma: A systematic review and meta-analysis.Annals of hepato-biliary-pancreatic surgery · 2024Review
- Development of prognostic models for advanced multiple hepatocellular carcinoma based on Cox regression, deep learning and machine learning algorithms.Frontiers in medicine · 2024Article
- Association between surgery treatment delays and survival outcomes in patients with esophageal cancer in Hebei, China.Frontiers in oncology · 2024Article
- Competing risks analysis of external versus internal radiation in patients with hepatocellular carcinoma after controlling for immortal time bias.Journal of cancer research and clinical oncology · 2023Article
- Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study.BMC health services research · 2023Article
- Surgical Delay Increases the Perioperative Blood Transfusion Rate In Percutaneous Nephrolithotomy.Sisli Etfal Hastanesi tip bulteni · 2023Article
- Effect of multidisciplinary team care on patient survival in chronic hepatitis B or C hepatocellular carcinoma.Frontiers in oncology · 2023Article
- Survival outcomes following treatment delays among patients with early-stage female cancers: a nationwide study.Journal of translational medicine · 2022Article
- Identification of diffusion weighted imaging would be affected before and after Gd-EOB-DTPA in patients with focal hepatic lesions: an observational study.Annals of translational medicine · 2022Article
- Impact of waiting time on hepatocellular carcinoma progression in patients undergoing curative tumour ablation.Quantitative imaging in medicine and surgery · 2022Article
- Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact.Hepatology communications · 2022Article
- Time interval from last visit to imaging diagnosis influences outcome in pancreatic adenocarcinoma: A regional population-based study on linked medico-administrative and clinical data.Therapeutic advances in medical oncology · 2022Article
- Clinical value of prophylactic transcatheter arterial chemoembolization treatment in patients with hepatocellular carcinoma.American journal of translational research · 2022Article
- Computer-aided diagnosis of hepatocellular carcinoma fusing imaging and structured health data.Health information science and systems · 2021Article
- Isotretinoin and Thalidomide Down-RegulateMolecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLiver cancer is the fifth most common cancer in men and the ninth most common cancer in women, and the WHO expects that there will be 1,341,344 cases in 2034 worldwide. Liver cancer also has the second-highest cancer death rate, accounting for 7% of all cancers. The study is going to explore the relationship between time interval from diagnosis to treatment and survival status of early-stage liver cancer patients. MATERIALS AND
methodsThis is a retrospective cohort study using the national database from Taiwan. The datasets include the Taiwan Cancer Registry Database (TCR), the National Health Insurance Research Database (NHIRD), and the National Registry of Deaths. The target population for the study was patients newly diagnosed with stage I and stage II liver cancer between the years 2004 and 2010. Total of 26,038 cases were included in the study. Except descriptive analysis, the relationship between patient characteristics and the time interval from diagnosis to treatment was examined by chi-square tests. In addition, modified Cox proportional hazard models were used to analyze the hazard ratio of patient death with various treatment delay durations.
resultsThere were 20,430 patients (78.46%) who received treatment less than 30 days after diagnosis, while 2,674 patients (10.27%) received treatment between 31 and 60 days after diagnosis, and 2,068 patients (7.94%) received treatment between 61 and 180 days after diagnosis, and 866 patients (3.33%) who received treatment 181 days after diagnosis. Those treated more than 181 days and 61-180 days after diagnosis had a 1.68-fold increased risk of death (95% confidence interval: 1.50-1.88) and a 1.39-fold increased risk of death (95% confidence interval: 1.31-1.17), respectively. Being male, being elderly, having a higher CCI level, and being treated in a hospital with a low service volume were factors associated with a poorer prognosis.
conclusionOverall, this study utilized a national cohort to conclude that for early-stage liver cancer patients, a longer the time interval from diagnosis to treatment results in a lower survival rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.